LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Wednesday that it has filed additional patents to protect its proprietary LX2 genetic analyzer technology.
The company said the three US patent applications seek to provide continuing and additional coverage of its LX2 technology: the unique sample prep DNA extraction method, the data and image processing algorithms, and the fast DNA-analysis function of the instrument and system.
LexaGene, based in Beverly, Massachusetts, is pioneering the first fully automated pathogen detection platform for use in diagnostics and sample analysis via its LX Analyzer.
The key feature is the open access nature of the genetic analyzer that allows end users to customize the instrument to target any pathogen of interest. The instrument is able to process multiple samples at a time, returning results within around one hour.
“Protecting our technology is critical for building value in the company,” said CEO Dr Jack Regan.
“These patent applications further defend our LX technology as being the first sample-to-answer microfluidic genetic analyzer that utilizes disposable cartridges and bulk fluid reservoirs for rapid and cost-efficient PCR (polymerase chain reaction) that can screen for many genetic targets at once.”
LexaGene's stock recently traded up 2.9% to C$0.70 a share in Toronto and rose 1.9% to US$0.54 in New York.
-- Updates stock price --
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham